ILUVIEN (Specialised Therapeutics Alim Pty Ltd)
Product name
ILUVIEN
Date registered
Evaluation commenced
Decision date
Approval time
206 working days (255)
Active ingredients
fluocinolone acetonide
Registration type
EOI
Indication
ILUVIEN (intravitreal implant) is now also indicated for the treatment of diabetic macular oedema (DME) in patients who have been previously treated with a course of corticosteroids and did not have a clinically significant rise in intraocular pressure (IOP).